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EDITORIAL COMMENT
Management of Patients With
Acute Myocardial Infarction and
End-Stage Renal Disease*
C. Richard Conti, MD, MACC
Gainesville, Florida
I suppose most physicians, particularly cardiologists, are
aware of the malignant nature of the combination of severe
end-stage renal disease (ESRD) and symptomatic coronary
artery disease. The term “end-stage renal disease” is often
used rather casually in patients whose renal function is not
normal. In my view, ESRD should include only long-term
dialysis patients who are candidates for renal transplantation
or who have undergone renal transplantation. I suspect that
those who have undergone renal transplantation have a
better prognosis than those patients who remain with
long-term dialysis treatment.
In a Medline search, I was able to find three articles
published in peer-reviewed journals dealing with the subject
of acute myocardial infarction (AMI) and renal dysfunction.
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The first article is by Wright et al. (1) and is entitled
“Acute Myocardial Infarction and Renal Dysfunction: A
High-Risk Combination.” These investigators compared
outcomes after AMI in patients with varying levels of renal
disease and in patients without renal failure. They studied
3,106 patients in a retrospective fashion. They divided their
patients into ESRD, severe renal insufficiency, moderate
renal dysfunction, mild chronic renal insufficiency, or no
renal disease. They defined these subsets on the basis of
creatinine clearance. The mortality was as one might pre-
dict. Death rates were 2% in patients with normal renal
function, 6% in those with mild renal failure, 14% in those
with moderate renal failure, 21% in those with severe renal
failure, and 30% in those with ESRD. Similar trends were
noted after discharge from hospital.
These investigators also pointed out that patients with
renal failure received adjunctive and reperfusion therapies
less frequently than those with normal renal function,
despite the fact that therapies such as acute reperfusion
therapy, aspirin, and beta-blockers decreased mortality in
patients receiving these therapies.
The second paper by Shlipak et al. (2) is entitled
“Association of Renal Insufficiency With Treatment and
Outcomes After Myocardial Infarction in Elderly Patients.”
This was a large cohort study consisting of 130,099 elderly
patients with myocardial infarction (MI) hospitalized be-
tween April 1994 and July 1995. The investigators wished
to determine how patients with renal insufficiency are
treated during hospitalization for MI and to determine the
association of renal insufficiency with survival after MI.
Patients were classified into subsets of no renal insufficiency,
mild renal insufficiency, or moderate renal insufficiency.
None of these patients was considered to have ESRD.
Results indicated that one-year mortality was 24% in pa-
tients with no renal insufficiency, 46% in patients with mild
renal insufficiency, and 66% in patients with moderate renal
insufficiency. Interestingly, patients with moderate renal
insufficiency were less likely to receive aspirin, beta-blockers,
or thrombolytic therapy.
The third publication by McCullough et al. (3) is entitled
“Benefits of Aspirin and Beta-Blockade After Myocardial
Infarction in Patients With Chronic Kidney Disease.”
These investigators indicated that until that point there had
been no randomized trials of cardioprotective therapy after
AMI in patients with chronic kidney disease, who should be
largely eligible for aspirin and beta-blockers as a base of
therapy. They analyzed a coronary care unit registry of 1,724
patients with ST-segment elevation MI and found that
usage of aspirin and beta-blockers in these patients was
52.3%, beta-blockers alone 19%, aspirin alone 15.2%, and
no aspirin or beta-blockers 13.5%. The main reasons for
absence of aspirin and beta-blockers were heart failure upon
admission, left bundle branch block, atrial and ventricular
arrhythmias, and shock. The corrected creatinine clearance
values also influenced the use of aspirin in beta-blockers. In
this observational study, if the creatinine clearance was81,
63.9% were given aspirin and beta-blockers; if the creatinine
clearance was 81 to 63, 55.8% received aspirin and beta-
blockers; if the creatinine clearance was 63.1 to 46.2, 48.2%
received aspirin and beta-blockers; and if the creatinine
clearance was 46.2 ml/min, only 35% of patients received
aspirin and beta-blockers. Aspirin and beta-blockers were
used in 40.4% of patients receiving dialysis. These investi-
gators concluded that aspirin and beta-blockers were under-
used in patients with AMI who have underlying kidney
disease.
In this issue of the Journal, Berger et al. (4) report on the
use of aspirin and beta-blocker therapy in patients with
ESRD and AMI. This is an observational study based on a
retrospective chart analysis of data collected between 1994
and 1996, which the authors contend provides the first
comprehensive analysis of AMI therapies among patients
with ESRD and in turn provides a baseline measure of
medical therapy delay. The message that the authors want
to convey is that ESRD patients are less likely to be treated
with aspirin and beta-blockers for their AMI than patients
who do not have ESRD. They further contend that lower
usage of beta-blockers and particularly aspirin may contrib-
ute to the increased mortality in patients with AMI who
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have ESRD. In this study, data were obtained from 145,740
patients without ESRD and 1,025 with ESRD. The authors
also point out that patients with ESRD have not been
represented in randomized AMI trials. This, of course, is
one of the limitations of all randomized trials that tend to
exclude patients with severe disease of systems other than
the heart.
The patient cohort was derived from the Cooperative
Cardiovascular Project national sample and was restricted to
patients age 65 years and older. Diagnosis of MI was made
by traditional means but did not include the cardiac marker
troponin. If this study is ever repeated, obviously troponin T
or I will be an important marker for AMI.
Although beta-blockers and aspirin were not used as
commonly in the ESRD patients as they were in patients
without ESRD, the benefits of beta-blocker use were not
statistically different between the dialysis and non-dialysis
groups. However, beta-blocker use was associated with 13%
absolute reduction in mortality in both the dialysis and
non-dialysis groups.
The authors wish to have their data serve as a stimulus to
more aggressive therapies for ESRD patients who are
having an AMI. I share that goal.
The combination of cardiovascular disease and renal
disease in the same patient is something that cardiologists
do not particularly like. However, it is an important area,
and the article by Berger and colleagues may help improve
our care of these complex patients. These patients are
extremely high risk and probably deserve to be treated with
aspirin and beta-blockers more than patients who do not
have ESRD.
Obviously, those of us who are taking care of patients
with AMI, with or without ESRD, do not consider aspirin
and beta-blockers as sole therapies for these patients. All of
these high-risk patients need to be considered for statin
therapy and angiotensin-converting enzyme inhibition as
well as beta-blockers and aspirin. This observational study
heightens the level of awareness about the seriousness of the
combination of MI and renal disease and reminds us that we
must be aggressive in the management of patients with
ESRD.
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